Melanocortin receptors in GtoPdb v.2023.1

Vanni Caruso, Biao-Xin Chai, Adrian J. L. Clark, Roger D. Cone, Alex N. Eberle, Sadaf Farooqi, Tung M. Fong, Ira Gantz, Carrie Haskell-Luevano, Victor J. Hruby, Kathleen G. Mountjoy, Colin Pouton, Helgi Schiöth, Jeffrey B. Tatro, Jarl E. S. Wikberg
{"title":"Melanocortin receptors in GtoPdb v.2023.1","authors":"Vanni Caruso, Biao-Xin Chai, Adrian J. L. Clark, Roger D. Cone, Alex N. Eberle, Sadaf Farooqi, Tung M. Fong, Ira Gantz, Carrie Haskell-Luevano, Victor J. Hruby, Kathleen G. Mountjoy, Colin Pouton, Helgi Schiöth, Jeffrey B. Tatro, Jarl E. S. Wikberg","doi":"10.2218/gtopdb/f38/2023.1","DOIUrl":null,"url":null,"abstract":"Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test. setmelanotide was approved by the US FDA for weight management in patients with POMC, PCSK1 or LEPR defiency, bremelanotide was approved by the US FDA for generalized hypoactive sexual desire disorder in premenopausal women, and NDP-MSH (afamelanotide) was approved by the EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.","PeriodicalId":14617,"journal":{"name":"IUPHAR/BPS Guide to Pharmacology CITE","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IUPHAR/BPS Guide to Pharmacology CITE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2218/gtopdb/f38/2023.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test. setmelanotide was approved by the US FDA for weight management in patients with POMC, PCSK1 or LEPR defiency, bremelanotide was approved by the US FDA for generalized hypoactive sexual desire disorder in premenopausal women, and NDP-MSH (afamelanotide) was approved by the EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.
黑色素皮质素受体在GtoPdb v.2023.1
黑素皮质素受体(NC-IUPHAR推荐的临时命名[41])被黑素皮质素家族成员(α-MSH, β-MSH和γ-MSH形式;δ型在哺乳动物中未发现)和促肾上腺皮质激素(ACTH)。内源性拮抗剂包括刺虱和刺虱相关蛋白。ACTH(1-24)已被美国FDA批准作为肾上腺功能检测的诊断试剂。setmelanotide被美国FDA批准用于POMC、PCSK1或LEPR缺乏症患者的体重管理,bremelanotide被美国FDA批准用于绝经前妇女的广泛性性欲减退,NDP-MSH (afamelanotide)被EMA批准用于治疗红细胞生成性原卟啉症。几种合成的黑素皮质素受体激动剂正在临床开发中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信